author keywords: horse; colic; endotoxaemia; flunixin meglumine; firocoxib; clinical study

MeSH headings : 4-Butyrolactone / administration & dosage; 4-Butyrolactone / analogs & derivatives; 4-Butyrolactone / therapeutic use; Animals; Anti-Inflammatory Agents, Non-Steroidal / administration & dosage; Anti-Inflammatory Agents, Non-Steroidal / therapeutic use; Clonixin / administration & dosage; Clonixin / analogs & derivatives; Clonixin / therapeutic use; Female; Horse Diseases / drug therapy; Horses; Intestinal Obstruction / complications; Intestinal Obstruction / veterinary; Male; Pain, Postoperative / drug therapy; Pain, Postoperative / veterinary; Random Allocation; Sulfones / administration & dosage; Sulfones / therapeutic use

TL;DR: Treatment of post-surgical SISO horses with firocoxib (COX-2 selective) would reduce the signs of endotoxaemia to a greater extent than flunixin meglumine (nonselective COX inhibitor) while continuing to provide similar levels of pain control. (via Semantic Scholar)